We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF
IDNA

73 hedge funds and large institutions have $57.1M invested in iShares Genomics Immunology and Healthcare ETF in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.27% less ownership

Funds ownership: 31.61% → 30.34% (-1.3%)

15% less funds holding

Funds holding: 86 → 73 (-13)

23% less capital invested

Capital invested by funds: $73.8M → $57.1M (-$16.7M)

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

50% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 22

Holders
73
Holders Change
-13
Holders Change %
-15.12%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
22
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WBG
Wharton Business Group
Pennsylvania
+$2.25M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.85M
3
Jane Street
Jane Street
New York
+$1.41M
4
WAP
Wealthcare Advisory Partners
Pennsylvania
+$1.23M
5
Goldman Sachs
Goldman Sachs
New York
+$1.14M

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$6.06M
2
AWS
Atria Wealth Solutions
New York
-$1.53M
3
FTUS
Flow Traders U.S.
New York
-$1.49M
4
JMPWA
JP Morgan Private Wealth Advisors
California
-$1.14M
5
UBS Group
UBS Group
Switzerland
-$945K
Name Holding Trade Value Shares
Change 		Change in
Stake
National Bank of Canada
51
National Bank of Canada
Quebec, Canada
$17K -$24.6K -825 -58%
Rockefeller Capital Management
52
Rockefeller Capital Management
New York
$14K -$480K -16,086 -97%
Citigroup
53
Citigroup
New York
$12K – – –
KTC
54
Kistler-Tiffany Companies
Pennsylvania
$10K – – –
NSIM
55
North Star Investment Management
Illinois
$9K – – –
SWM
56
Sugarloaf Wealth Management
Georgia
$9K – – –
HI
57
Harbour Investments
Wisconsin
$9K +$9.19K +308 New
FDCDDQ
58
Federation des caisses Desjardins du Quebec
Quebec, Canada
$8.67K – – –
TWM
59
Tradition Wealth Management
Minnesota
$7K +$30 +1 +0.4%
TFS
60
TrustCore Financial Services
Tennessee
$6K – – –
TF
61
TimeScale Financial
Massachusetts
$5K – – –
Simplex Trading
62
Simplex Trading
Illinois
$4K +$2.98K +100 +233%
WIM
63
Westside Investment Management
California
$3.52K – – –
CCM
64
Covington Capital Management
California
$3K – – –
WAM
65
Worth Asset Management
Texas
$3K – – –
EIP
66
Ellis Investment Partners
Pennsylvania
$3K +$30 +1 +0.8%
SMG
67
Spectrum Management Group
Indiana
$2K – – –
Qube Research & Technologies (QRT)
68
Qube Research & Technologies (QRT)
United Kingdom
$2K +$1.67K +56 New
VNA
69
Valley National Advisers
Pennsylvania
$1K – – –
Bank of Montreal
70
Bank of Montreal
Ontario, Canada
$83 – – –
AWS
71
Atria Wealth Solutions
New York
– -$1.53M -44,313 Closed
FTUS
72
Flow Traders U.S.
New York
– -$1.49M -43,315 Closed
WGCA
73
Wolf Group Capital Advisors
Virginia
– -$654K -18,992 Closed
Citadel Advisors
74
Citadel Advisors
Florida
– -$571K -16,584 Closed
SWA
75
Stratos Wealth Advisors
Ohio
– -$545K -15,814 Closed
1 2
3
4

IDNA Hedge Fund Activity: Q2 2022 in Review

73 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q2 2022, worth a combined $57.1M — down 23% from $73.8M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of IDNA and 11 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 15 added.

The largest buyer was Wharton Business Group, adding an estimated $2.25M. The largest seller was Bank of America, cutting an estimated $6.06M.

  • 73 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q2 2022, down from 86 in Q1 2022.
  • Funds reported $57.1M of iShares Genomics Immunology and Healthcare ETF stock for Q2 2022, down 23% quarter-over-quarter.
  • 11 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q2 2022 and 22 closed out, a net change of -11 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q2 2022 was Wharton Business Group, an estimated $2.25M added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q2 2022 was Bank of America, an estimated $6.06M sold.

Based on aggregated 13F filings for Q2 2022.